Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

0.9678 +0.0167 (+1.76%)
Streaming Delayed Price Updated: 10:30 AM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
From Tempest Therapeutics
Via GlobeNewswire
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Year End 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Tempest Therapeutics Announces Up To $6 Million Private Placement
$2 million upfront with up to approximately $4 million of potential aggregate gross proceeds upon the exercise in full of warrants 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
From Tempest Therapeutics
Via GlobeNewswire
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
From Tempest Therapeutics
Via GlobeNewswire
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants 
From Tempest Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition
San Francisco, CA – November 19, 2025 – Tempest Therapeutics, Inc. (NASDAQ: TPST) saw its stock price plummet by a staggering 48.92% today, wiping out nearly half of its market value in a single... 
Via MarketMinute
News headline image
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗
The transaction is expected to close in early 2026, provided it receives all required approvals. 
Via Stocktwits
News headline image
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast ↗
 
Via Benzinga
News headline image
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today ↗
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. 
Via Benzinga
News headline image
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
From Tempest Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.